A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of DDP733 in Female Patients With Irritable Bowel Syndrome With Constipation
Sponsor: Dynogen Pharmaceuticals
Listed as NCT00547469, this PHASE2/PHASE3 trial focuses on Irritable Bowel Syndrome and remains ongoing. Sponsored by Dynogen Pharmaceuticals, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dynogen Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .